Pulsenmore Ltd. Announces Financial Results and Business Highlights for the First Half of 2026

Pulsenmore Ltd. Announces Financial Results and Business Highlights for the First Half of 2026 Management to Host Webcast today at 8:30 am ET to discuss Results and Provide Business Update

OMER, Israel, Aug. 31, 2026 /PRNewswire/ -- Pulsenmore Ltd. (NASDAQ: PLSM) (TASE: PLSM), a leading innovator in remote maternal-fetal healthcare and home ultrasound solutions, presents the key operational, commercial, regulatory, and technological achievements as well as financial updates for the six month period ended June 30, 2026.

During the first half of 2026, Pulsenmore advanced its commercialization efforts in the United States following FDA marketing authorization for its home ultrasound platform, while continuing to advance product development, regulatory approvals, prepare for manufacturing and pursue strategic collaborations.

H1 2026 Highlights

Commercial & Business Development

Strategic Partnerships & Healthcare Expansion

Product Development & Technology

Manufacturing & Operations

Intellectual Property

Pulsenmore strengthened its intellectual property portfolio with multiple newly granted patents during H1 2026, including patents related to:

Regulatory Achievements

Key regulatory milestones achieved during H1 2026 included:

Private Placement with a Single Healthcare Focused Institutional Investor

In June 2026, the Company entered into a securities purchase agreement with a healthcare-focused institutional investor, for the purchase and sale of 1,562,500 pre-funded warrants and ordinary warrants to purchase up to 1,562,500 ordinary shares in a private placement at a combined purchase price of $4.7999 per pre-funded warrant and accompanying ordinary warrant), representing a premium to the then Nasdaq Minimum Price under Nasdaq rules.

The gross proceeds from the offering were NIS 22.5 million (approximately $7.5 million), before deducting placement agent commissions and other offering expenses.

Management Commentary

"The first half of 2026 marked a transformative period for Pulsenmore as we initiated commercial operations in the United States following FDA authorization and achieved multiple strategic milestones across commercialization, regulation, manufacturing, and innovation," said Dr. Elazar Sonnenschein, Chief Executive Officer of Pulsenmore Ltd. "As we move into the second half of the year, our focus is on scaling the commercial base and converting the early stages of this year to actual revenues. We believe our achievements to date position Pulsenmore for continued growth as we expand access to remote maternal-fetal healthcare worldwide."

Financial Results for the period ended June 30, 2026

Webcast Details

Pulsenmore will host a webcast to review the results today on August 31 at 8:30am Eastern Time / 3:30pm Israel Time.

Webcast: https://teams.microsoft.com/meet/35050418577919?p=r5gfAIMDL65KJ8zKj3

A replay of the webcast will be available following the call on the Company's Investor Relations website at: https://pulsenmore.com/investor_relations

About Pulsenmore Ltd.

Pulsenmore Ltd. (Nasdaq/TASE: PLSM) is a healthcare technology company focused on transforming maternal-fetal healthcare through remote ultrasound and telemedicine solutions. The Company develops self-use and remote clinical ultrasound systems designed to improve accessibility, continuity of care, and patient engagement in pregnancy monitoring.

For more information, visit: www.pulsenmore.com

Forward-Looking Statements

This press release contains forward-looking statements. In particular, statements using words such as "may," "seek," "will," "consider," "likely," "assume," "estimate," "expect," "anticipate," "intend," "believe," "contemplate," "do not believe," "aim," "goal," "due," "predict," "plan," "project," "continue," "potential," "positioned," "guidance," "objective," "outlook," "trends," "future," "could," "would," "should," "target," "on track" or their negatives or variations, and similar terminology and words of similar import, generally involve future or forward-looking statements. Such forward-looking statements include, but are not limited to, statements relating to Pulsenmore's continued commercial momentum, potential expansion in the United States, opportunities, expected benefits and outcomes of collaborations and strategic partnerships, and planned manufacturing expansion and automated manufacturing operations. Forward-looking statements reflect Pulsenmore's current views, plans, or expectations with respect to future events or financial performance. They are inherently subject to significant business, economic, competitive, and other risks, uncertainties, and contingencies. Forward-looking statements are based on Pulsenmore's current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including, but not limited to, the following: the Company's lack of operating history; the Company's current and future capital requirements and the Company's belief that its existing cash will be sufficient to fund its operations for more than one year from the date that the financial statements are issued; the Company's ability to manufacture, market and sell its products and to generate revenues; the Company's ability to maintain its relationships with key partners and grow relationships with new partners; the Company's ability to maintain or protect the validity of its U.S. and other patents and other intellectual property; the Company's ability to launch and penetrate markets in new locations and new market segments; the Company's ability to retain key executive members and hire additional personnel; the Company's ability to maintain and expand intellectual property rights; interpretations of current laws and the passages of future laws; the Company's ability to achieve greater regulatory compliance needed in existing and new markets; the Company's ability to achieve key performance milestones in its planned operational testing; the Company's ability to establish adequate sales, marketing and distribution channels; security, political and economic instability in the Middle East that could harm its business; and acceptance of the Company's business model by investors. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company's reports filed from time to time with the SEC, including, but not limited to, the risks, uncertainties and other factors included in the Company's Annual Report on Form 20-F for the fiscal year ended December 31, 2025 and in subsequent filings with the SEC. The inclusion of forward-looking statements in this or any other communication should not be considered as a representation by Pulsenmore or any other person that current plans or expectations will be achieved. Forward-looking statements speak only as of the date on which they are made, and Pulsenmore undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments, or otherwise, except as otherwise required by law.

The financial information is presented in NIS millions (unless otherwise stated) and the figures presented are rounded accordingly. The convenience translations of the New Israeli Shekel (NIS) figures into US Dollars were made at the rate of exchange prevailing on June 30, 2026: US $1.00 equals NIS 2.978. The translations were made purely for the convenience of the reader.

Investor Contact

Miri Segal-Scharia MS-IR LLC

[email protected]

PULSENMORE LTD.

CONDENSED CONSOLIDATED INTERIM STATEMENTS OF FINANCIAL POSITION (UNAUDITED)

Convenience

translation

into

U.S. dollars

(see note 2(b))

December 31,

June 30,

2025

2026

NIS in thousands

in thousands

Assets

CURRENT ASSETS

Cash and cash equivalents

21,604

43,584

14,635

Short-term bank deposits

47,531

26,180

8,791

Restricted deposits

140

Trade receivables

4,144

2,382

800

Other receivables

1,391

1,832

615

Inventory – current portion

6,593

6,345

2,131

Total current assets

81,403

80,323

26,972

NON-CURRENT ASSETS

Inventory – non-current portion

13,337

13,742

4,615

Right-of-use assets

1,285

752

253

Property and equipment, net

5,822

5,089

1,709

Total non-current assets

20,444

19,583

6,577

Total assets

101,847

99,906

33,549

Liabilities and equity

CURRENT LIABILITIES

Trade payables

1,980

3,463

1,163

Warrants

33,198

11,148

Other payable and accruals

4,407

4,121

1,384

Contract liabilities

938

Share-based compensation liability

276

278

Current maturities of liability for royalties to the

Israel Innovation Authority

1,705

1,693

569

Current maturities of lease liabilities

1,023

840

282

Total current liabilities

10,329

43,674

14,666

NON-CURRENT LIABILITIES

Liability for royalties to the Israel Innovation

Authority, net of current maturities

7,886

7,575

2,544

Lease liabilities, net of current maturities

542

319

107

Total non-current liabilities

8,428

7,894

2,651

Total liabilities

18,757

51,568

17,317

EQUITY

Ordinary shares

Share premium

256,137

86,009

Capital reserve

10,092

10,412

3,497

Accumulated deficit

(183,141)

(218,213)

(73,275)

Total equity

83,090

48,338

16,232

Total liabilities and equity

101,847

99,906

33,549

PULSENMORE LTD.

CONDENSED CONSOLIDATED INTERIM STATEMENTS OF COMPREHENSIVE LOSS

(UNAUDITED)

Convenience

translation into

U.S. dollars

(see note 2(b))

Six months ended June 30,

2025

2026

NIS in thousands

(except per share data)

in thousands

(except per

share data)

Revenues

3,999

6,080

2,042

Cost of revenues

2,542

3,855

1,294

Gross profit

1,457

2,225

748

Research and development expenses, net

8,029

8,459

2,840

Sales and marketing expenses

5,966

6,382

2,143

General and administrative expenses

8,083

8,141

2,734

Operating loss

20,621

20,757

6,969

Financial expenses

4,766

15,962

5,359

Financial income

(2,231)

(1,647)

(553)

Financial expenses, net

2,535

14,315

4,806

Loss before income tax

23,156

35,072

11,775

Provision for income tax

Net loss and comprehensive loss

23,157

35,072

11,775

Loss per ordinary share – basic and diluted (*)

3.6

5.39

1.83

Weighted average ordinary shares outstanding

6,429,059

6,502,844

(*) Basic loss per share does not include the above-mentioned 1,562,500 pre-funded warrants since they are

accounted for as a liability. In addition, the impact of the pre-funded warrants has not taken in the diluted weighted

average number of ordinary shares calculation as their effect would have been anti-dilutive.

PULSENMORE LTD.

CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CHANGES IN EQUITY (UNAUDITED)

Ordinary shares

Share premium

Capital reserve

Accumulated

deficit

Total

NIS in thousands

Balance at January 1, 2025

253,205

10,968

(167,288)

96,887

Changes in the six month period ended June 30, 2025:

Net loss and comprehensive loss for the year

(23,157)

Share-based compensation

506

Exercise of options

471

(199)

272

Expiration of options

280

(280)

Balance at June 30, 2025

253,956

10,995

(190,445)

74,508

Balance at January 1, 2026

256,137

10,092

(183,141)

83,090

Changes in the six month period ended 31June 30, 2026:

Net loss and comprehensive loss for the year

(35,072)

Share-based compensation

320

Balance at June 30, 2026

256,137

10,412

(218,213)

48,338

* Less than NIS 1 thousand

PULSENMORE LTD.

CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CHANGES IN EQUITY (UNAUDITED)

Convenience translation into U.S. dollars (see note 2(b))

in thousands

Ordinary shares

Share premium

Capital reserve

Accumulated

deficit

Total

Balance at January 1, 2026

86,009

3,390

(61,500)

27,900

Changes in the six month period ended

June 30, 2026:

Net loss and comprehensive loss for the year

(11,775)

Share-based compensation

107

Balance at June 30, 2026

86,009

3,497

(73,275)

16,232

PULSENMORE LTD.

CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS

Convenience

translation into

U.S. dollars

(see note 2(b))

Six months ended June 30,

2025

2026

NIS in thousands

in thousands

Net cash used in operating activities (see appendix)

(15,570)

(17,571)

(5,900)

Cash Flows from Investing Activities

Purchase of property and equipment

(97)

(134)

(45)

Proceeds from (investment in) short-term deposits

(2,289)

19,231

6,458

Interest received

964

1,291

434

Net cash provided by (used in) investing activities

(1,422)

20,388

6,847

Cash Flows from Financing Activities

Proceeds from private placement

22,507

7,558

Transaction costs related to private placement

(1,738)

(584)

Exercise of options

Payment to the Israel Innovation Authority

(287)

(160)

(53)

Receipt of grants from Israel Innovation Authority

1,319

Principal portion of lease payments

(574)

(652)

(218)

Interest portion of lease payments

(94)

(59)

(20)

Net cash provided by in financing activities

368

19,898

6,683

Increase (decrease) in cash and cash equivalents

(16,624)

22,715

7,630

Cash and cash equivalents at beginning of the period

41,170

21,604

7,255

Exchange differences on cash and cash equivalents

(105)

(735)

(250)

Cash and cash equivalents at end of the period

24,441

43,584

14,635

PULSENMORE LTD.

CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS

Appendix to the statements of cash flows

Convenience

translation into

U.S. dollars

(see note 2(b))

Six months ended June 30,

2025

2026

NIS in thousands

in thousands

Net loss

(23,157)

(35,072)

(11,775)

Adjustments for:

Depreciation and amortization

1,432

1,521

511

Share-based compensation

506

320

107

Financial expenses (income)

(15)

12,527

4,207

Exchange differences

3,356

1,627

546

5,279

15,995

5,371

Changes in operating asset and liability items:

Decrease in trade receivables

1,240

1,762

592

Increase in other receivables

(22)

(441)

(149)

Increase (decrease) in inventory

1,465

(157)

(53)

Increase (decrease) in trade payables

(207)

1,483

498

Decrease in other payables and accruals

(379)

(286)

(97)

Increase (decrease) in contract liabilities

193

(857)

(288)

Increase in liability of share-based compensation

2,308

1,506

504

Net cash used in operating activities

(15,570)

(17,571)

(5,900)

Supplemental information on non-cash

transactions:

Changes in right-of-use asset and lease liabilities

110

Changes in share-based compensation liability

(268)

SOURCE Pulsenmore Ltd.